Literature DB >> 17194169

Drug-induced musculoskeletal disorders.

Bernard Bannwarth1.   

Abstract

Drug-induced musculoskeletal disorders represent a broad clinical spectrum, from asymptomatic biological abnormalities to severe and even life-threatening diseases. Since an increasing number of drugs have been implicated in inducing rheumatic symptoms and/or syndromes, this review is not meant to be exhaustive, bearing in mind that the development of any musculoskeletal disorder should be considered as possibly related to a medication. The purpose of this article is to provide an overview of the more frequent drug-induced musculoskeletal disorders. These include: (i) arthralgias and arthropathies, including chondropathies and inflammatory arthritis; (ii) connective tissue diseases, especially lupus-like syndromes; (iii) periarticular disorders, including tendinopathies, enthesopathies and frozen shoulder; (iii) bone diseases, such as osteoporosis, osteomalacia and osteonecrosis; and (iv) myopathies. Although virtually all drug classes may induce musculoskeletal disorders, a significant part of them are related to corticosteroids, vaccines, antibacterials and lipid-lowering agents. Knowledge of drug-induced musculoskeletal disorders avoids carrying out unnecessary investigations, and allows optimal management of the patients, i.e. early discontinuation of the offending agent, adequate treatment monitoring and/or intervention with appropriate preventive actions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17194169     DOI: 10.2165/00002018-200730010-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


  136 in total

1.  Fluoroquinolones and risk of Achilles tendon disorders: case-control study.

Authors:  P D van der Linden; M C J M Sturkenboom; R M C Herings; H G M Leufkens; B H Ch Stricker
Journal:  BMJ       Date:  2002-06-01

2.  Drugs and falls in later life.

Authors:  John Grimley Evans
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

Review 3.  Statin-associated myopathy.

Authors:  Paul D Thompson; Priscilla Clarkson; Richard H Karas
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

4.  Reflex sympathetic dystrophy associated with antiepileptic drugs.

Authors:  G F Falasca; T M Toly; A J Reginato; P L Schraeder; C R O'Connor
Journal:  Epilepsia       Date:  1994 Mar-Apr       Impact factor: 5.864

5.  Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty.

Authors:  W N Roberts; E A Babcock; S A Breitbach; D S Owen; W R Irby
Journal:  J Rheumatol       Date:  1996-06       Impact factor: 4.666

6.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.

Authors:  T P van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  Rheumatology (Oxford)       Date:  2000-12       Impact factor: 7.580

Review 7.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

Review 8.  Rheumatological complications associated with the use of indinavir and other protease inhibitors.

Authors:  E Florence; W Schrooten; K Verdonck; C Dreezen; R Colebunders
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

9.  Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs.

Authors:  Robert A Adler; Marc C Hochberg
Journal:  Arch Intern Med       Date:  2003-11-24

Review 10.  Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.

Authors:  M G Cohen; M V Prowse
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 May-Jun
View more
  7 in total

1.  Criteria for environmentally associated autoimmune diseases.

Authors:  Frederick W Miller; K Michael Pollard; Christine G Parks; Dori R Germolec; Patrick S C Leung; Carlo Selmi; Michael C Humble; Noel R Rose
Journal:  J Autoimmun       Date:  2012-07-06       Impact factor: 7.094

Review 2.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

3.  Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.

Authors:  Quentin Dardonville; Esther Salguiero; Vanessa Rousseau; Leila Chebane; Jean Luc Faillie; Sophie Gautier; Jean Louis Montastruc; Alfonso Carvajal; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

4.  Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database.

Authors:  Hélène Géniaux; Denise Assaf; Ghada Miremont-Salamé; Bénédicte Raspaud; Amandine Gouverneur; Philip Robinson; Antoine Pariente; Francesco Salvo
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

Review 5.  Skeletal sequelae of cancer and cancer treatment.

Authors:  Charles J Stava; Camilo Jimenez; Mimi I Hu; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2009-05-02       Impact factor: 4.442

6.  Congenital Adrenal Hyperplasia in an Elite Female Soccer Player; What Sports Medicine Clinicians Should Know about This?

Authors:  Hooman Angoorani; Zohreh Haratian; Farzin Halabchi
Journal:  Asian J Sports Med       Date:  2012-09

7.  Inflammatory myopathy and severe rhabdomyolysis induced by leuprolide acetate therapy for prostate cancer: a case report.

Authors:  Michael Bergner; Martin Rohacek; Paul Erne
Journal:  J Med Case Rep       Date:  2011-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.